Trials / Terminated
TerminatedNCT05222607
Longitudinal Evaluation and Real-world Evidence of NT201
LONG RUN: LONGitudinal Evaluation and Real-world Evidence of Uniquely Purified incobotulinumtoxinA (Xeomin) in Treatment Naïve Participants
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 11 (actual)
- Sponsor
- Merz North America, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A (BoNT-A) treatment naïve participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IncobotulinumtoxinA | IncobotulinumtoxinA injections for aesthetic indications. |
Timeline
- Start date
- 2023-02-10
- Primary completion
- 2023-05-18
- Completion
- 2023-05-18
- First posted
- 2022-02-03
- Last updated
- 2023-06-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05222607. Inclusion in this directory is not an endorsement.